GlassScriptPhysician profile
Liliya Rozenfeld
NPI 1518526839
$3,479.40
in general payments reported to CMS, 2019-2025
28 companies · $977 in 2025
The $977 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $230 · 2022: $1,054 · 2023: $717 · 2024: $501 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,195.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $405.48 | 2022-2025 | |
| Abbvie INC. | $394.73 | 2021-2025 | |
| Evofem Biosciences, INC. | $300.65 | 2022-2025 | Phexxi, Solosec, Phexx |
| Biohaven Pharmaceutical Holding Company LTD. | $255.45 | 2022 | |
| Intra-Sana Laboratories | $200.00 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Organon LLC | $171.66 | 2021-2025 | Nexplanon |
| Exeltis, USA INC. | $167.41 | 2021-2024 | Slynd |
| Amgen INC. | $166.91 | 2022 | |
| Agile Therapeutics, INC. | $148.60 | 2021-2023 | Twirla |
| Nevro Corp. | $131.91 | 2024 | Senza |
| Millicent US INC | $129.49 | 2021-2025 | Intrarosa, Femring, Femlyv |
| Scynexis, INC. | $127.33 | 2022 | |
| Pfizer INC. | $109.25 | 2024-2025 | |
| Shield Therapeutics INC | $89.70 | 2022-2025 | Accrufer |
| Exact Sciences Corporation | $78.84 | 2023-2025 | Cologuard Collection Kit |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $77.78 | 2025 | Veozah |
| Myovant Sciences INC. | $75.48 | 2021-2022 | |
| Hologic Sales and Service, LLC | $72.11 | 2022-2024 | Myosure Tissue Removal Device, Omni Hysteroscope, Novasure |
| Myriad Women'S Health, INC. | $70.76 | 2023 | Myrisk |
| Avion Pharmaceuticals | $64.95 | 2021-2023 | Balcoltra |
| Sumitomo Pharma America, INC. | $50.61 | 2025 | Gemtesa |
| Forte Bio-Pharma LLC | $50.00 | 2023 | |
| Therapeuticsmd, INC. | $42.40 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.65 | 2022 | |
| Novo Nordisk INC | $21.12 | 2023 | Wegovy |
| Coopersurgical, INC. | $19.60 | 2022 | |
| Merck Sharp & Dohme LLC | $18.86 | 2021 | |
| Mycovia Pharmaceuticals, INC. | $15.67 | 2023 | Vivjoa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Liliya Rozenfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.